AbbVie’s RINVOQ Wins EC Approval to Treat Severe Alopecia Areata

AbbVie has received approval from the European Commission (EC) for RINVOQ (upadacitinib; 15 mg and 30 mg, once daily) to treat adults and adolescents aged 12 years and older with severe alopecia areata (AA). Alopecia areata is an autoimmune disorder that causes unpredictable hair loss, ranging from small bald patches on the scalp to complete […]